Condition: Newly Diagnosed Multiple Myeloma (NDMM) · Sponsor: Universiteit Antwerpen
This study investigates newly diagnosed multiple myeloma patients following standard of care treatment. The primary endpoint of the study is to determine minimal residual disease (MRD) by combining 2 techniques in order to better predict progression free survival (PFS) of a patient. Secondary endpoint is to gain more insight into diagnostic features to better stratify patients based on risk factors for early relapse. Both endpoints could lead to a more patient specific treatment in the future. Participants will be followed throughout their standard of care treatment. This treatment consists of indcution chemotherapy, followed by autologous stem cell transplant (ASCT), followed by lenalidomide maintenance therapy. * Before start of induction chemotherapy the patient will receive a whole-body FDG PET/LDCT scan and an additional bone marrow aspirate sample will be taken during a routine bone marrow punction. This sample will be used for whole exome sequencing (WES). * For those patients who achieve at least a very good partial response (VGPR) after induction chemotherapy and ASCT a repeat whole body FDG PET/LDCT scan will be performed before start of maintenance therapy. This scan will be repeated for a third time after 1 year of maintenance therapy. Besides this, an additional bone marrow aspirate sample will be taken for MRD detection. This will be done before start of maintenance therapy, after 1 year of maintenance therapy and after 2 years of maintenance therapy. MRD dete…
This description comes directly from the study's public registry record.
Sofie De Rechter · 03 821 31 43 · sofie.derechter@uantwerpen.be
Always discuss trial participation with your own doctor first.
| Universitair ziekenhuis Antwerpen | Antwerp, Antwerpen, Belgium | Recruiting |
| Universitair ziekenhuis Gent | Ghent, Oost Vlaandere, Belgium | Recruiting |
| Universitair Ziekenhuis Leuven | Leuven, Vlaams-Brabant, Belgium | Recruiting |
| AZ Sint-Jan Brugge | Bruges, West-Vlaandere, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07087964